Austar Lifesciences Limited (HKG:6118)

Market Cap	399.81M -1.3%
Revenue (ttm)	1.70B +2.0%
Net Income	37.62M +110.2%
EPS	0.07 +110.2%
Shares Out	512.58M
PE Ratio	10.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,000
Open	0.7900
Previous Close	0.7900
Day's Range	0.7600 - 0.7900
52-Week Range	0.6500 - 1.9700
Beta	0.91
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 2, 2026

About Austar Lifesciences

Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through Integrated Process and Packaging Equipment & Systems (IPS); Consulting, Digitalization and Construction (CDC); and Life Science Equipment and Consumables (SIC) segments. The company also offers clean utility equipment and chemical pharmaceutical preparation systems; bioprocess equipment and systems; clean room, automation control, ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1991
• Employees: 1,468
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6118

Financial Performance

In 2025, Austar Lifesciences's revenue was 1.53 billion, an increase of 2.02% compared to the previous year's 1.50 billion. Earnings were 33.81 million, an increase of 110.24%.

Financial numbers in CNY